Marie Høxbro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marie Høxbro has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Sophie Homøe
Department of Otorhinolaryngology, Head and Neck Surgery and Audiology Copenhagen University Hospital Copenhagen Denmark
6 shared publications - Simon Høj
Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
5 shared publications - Vibeke Backer
Department of Otorhinolaryngology, Head & Neck Surgery, and Audiology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark
5 shared publications - Christian Korsgaard Pedersen
Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
4 shared publications - Christian von Buchwald
Department of Otorhinolaryngology, Head and Neck Surgery and Audiology Rigshospitalet, University of Copenhagen Copenhagen Denmark
4 shared publications - Jens Tidemandsen
Copenhagen University Hospital
4 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 11 (6)
No Effect of Preoperative Mepolizumab on Early Postoperative Healing After ESS for Severe CRSwNP
Objective: To evaluate postoperative endoscopic mucosal healing 2 weeks after ESS in patients with severe CRSwNP treated with surgery alone versus surgery combined with biologics initiated 2 weeks preoperatively. Methods: In this exploratory post hoc analysis, patients with severe CRSwNP were divided into two cohorts: ESS alone and ESS with preoperative mepolizumab initiated 2 weeks prior to surgery. Postoperative endoscopic video recordings obtained 2 weeks after ESS were anonymized and evaluated by four raters using blinded offline scoring. Healing was assessed using structured endoscopic domains (including discharge, edema, and scarring) and an overall endoscopic visual analogue scale (VAS 0–10). Inter‐rater reliability was assessed. Results: The overall endoscopic VAS score did not differ between groups. Consistent with this, no differences were observed in endoscopic scores. Inter‐rater agreement was moderate for VAS, discharge, and edema, and low for scarring, reflecting inherent limitations of early postoperative endoscopic assessment. Conclusion: In this exploratory analysis, preoperative mepolizumab was not associated with measurable differences in early postoperative endoscopic mucosal healing 2 weeks after ESS. These findings relate specifically to early postoperative mucosal appearance and should not be interpreted as evidence regarding the broader efficacy of biologic therapy or longer‐term postoperative outcomes. Larger prospective studies with longer follow‐up are warranted. Level of Evidence: 2.
- 29 October 2026
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 11 (6)
Open AccessNo Effect of Preoperative Mepolizumab on Early Postoperative Healing After ESS for Severe CRSwNP
Objective: To evaluate postoperative endoscopic mucosal healing 2 weeks after ESS in patients with severe CRSwNP treated with surgery alone versus surgery combined with biologics initiated 2 weeks preoperatively. Methods: In this exploratory post hoc analysis, patients with severe CRSwNP were divided into two cohorts: ESS alone and ESS with preoperative mepolizumab initiated 2 weeks prior to surgery. Postoperative endoscopic video recordings obtained 2 weeks after ESS were anonymized and evaluated by four raters using blinded offline scoring. Healing was assessed using structured endoscopic domains (including discharge, edema, and scarring) and an overall endoscopic visual analogue scale (VAS 0–10). Inter‐rater reliability was assessed. Results: The overall endoscopic VAS score did not differ between groups. Consistent with this, no differences were observed in endoscopic scores. Inter‐rater agreement was moderate for VAS, discharge, and edema, and low for scarring, reflecting inherent limitations of early postoperative endoscopic assessment. Conclusion: In this exploratory analysis, preoperative mepolizumab was not associated with measurable differences in early postoperative endoscopic mucosal healing 2 weeks after ESS. These findings relate specifically to early postoperative mucosal appearance and should not be interpreted as evidence regarding the broader efficacy of biologic therapy or longer‐term postoperative outcomes. Larger prospective studies with longer follow‐up are warranted. Level of Evidence: 2.
- 20 August 2026
- Published by SAGE Publications in American Journal of Rhinology & Allergy
AI-derived Histopathological Signatures Are Associated With Response to Mepolizumab in Chronic Rhinosinusitis With Nasal Polyps
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory disease with variable response to biologic therapy. Tissue-based predictors of treatment response are limited, and conventional eosinophil-focused histopathology has shown inconsistent predictive value. Objective: To assess whether artificial intelligence (AI)-derived baseline histopathology of nasal polyps contains information associated with clinical response to mepolizumab in CRSwNP. Methods: This hypothesis-generating substudy included patients with severe CRSwNP enrolled in a randomized controlled trial. Baseline biopsies were analysed using an AI-driven spatial histopathology pipeline extracting 84 morphological features per cell. Features were evaluated in eosinophil-only, noneosinophil, and all-cell configurations. Treatment response at 6 and 12 months was defined using EUFOREA criteria. Linear discriminant analysis and partial least squares regression were applied. Results: Fifty-eight patients were included. At 12 months, the eosinophil-only model showed limited discrimination (AUC ≈ 0.43), the noneosinophil model moderate discrimination (AUC ≈ 0.62), and the all-cell model the highest performance (AUC ≈ 0.75). At 6 months, all models showed limited discrimination (AUC ≈ 0.49). For continuous outcomes, noneosinophil models explained the greatest variance (R 2 up to ≈ 0.34). Conclusion: AI-derived baseline histopathology contains information associated with clinical response to mepolizumab in CRSwNP. Models incorporating the broader tissue microenvironment outperformed eosinophil-focused approaches, supporting the potential of computational pathology for pretreatment stratification of biologic therapy in CRSwNP.
- 20 August 2026
- Published by SAGE Publications in American Journal of Rhinology & Allergy
AI-derived Histopathological Signatures Are Associated With Response to Mepolizumab in Chronic Rhinosinusitis With Nasal Polyps
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory disease with variable response to biologic therapy. Tissue-based predictors of treatment response are limited, and conventional eosinophil-focused histopathology has shown inconsistent predictive value. Objective: To assess whether artificial intelligence (AI)-derived baseline histopathology of nasal polyps contains information associated with clinical response to mepolizumab in CRSwNP. Methods: This hypothesis-generating substudy included patients with severe CRSwNP enrolled in a randomized controlled trial. Baseline biopsies were analysed using an AI-driven spatial histopathology pipeline extracting 84 morphological features per cell. Features were evaluated in eosinophil-only, noneosinophil, and all-cell configurations. Treatment response at 6 and 12 months was defined using EUFOREA criteria. Linear discriminant analysis and partial least squares regression were applied. Results: Fifty-eight patients were included. At 12 months, the eosinophil-only model showed limited discrimination (AUC ≈ 0.43), the noneosinophil model moderate discrimination (AUC ≈ 0.62), and the all-cell model the highest performance (AUC ≈ 0.75). At 6 months, all models showed limited discrimination (AUC ≈ 0.49). For continuous outcomes, noneosinophil models explained the greatest variance (R 2 up to ≈ 0.34). Conclusion: AI-derived baseline histopathology contains information associated with clinical response to mepolizumab in CRSwNP. Models incorporating the broader tissue microenvironment outperformed eosinophil-focused approaches, supporting the potential of computational pathology for pretreatment stratification of biologic therapy in CRSwNP.
- Open Access
- 21 June 2026
- Published by Taylor & Francis in Acta Oto-Laryngologica
- Vol. 146 (10) , 1-9
The minimal clinically important difference for the Sniffin’ Sticks Identification Test-16 in patients with chronic rhinosinusitis with nasal polyps treated with biologics
The Minimal Clinically Important Difference (MCID) reflects the smallest change in a test score perceived as relevant by the patient. MCIDs vary according to disease and clinical context. The Sniffin' Sticks Identification Test 16 (SSIT-16) is a commonly used smell assessment tool, but its MCID in severe chronic rhinosinusitis with nasal polyps (CRSwNP) is unknown. To determine the MCID of SSIT-16 in severe CRSwNP treated with biologics. We analysed change scores from baseline to week 24 in 313 patients. The MCID was estimated using anchor-based and distribution-based methods. Anchors included a visual analogue scale (VAS) for smell, the rhinologic domain of SNOT-22, and the smell/taste item of SNOT-22. Distribution-based analyses included half a standard deviation of baseline SSIT-16 scores, the standard error of measurement (SEM), and the individual-level smallest detectable change. The smell VAS performed best and was therefore chosen as the primary anchor. The optimal ΔSSIT-16 cut-off, balancing sensitivity (78%) and specificity (84%), was 3.5 points. This estimate was supported by distribution-based, sensitivity, and subgroup analyses. An improvement of approximately 3.5 SSIT-16 points appears to reflect clinically meaningful change in biologically treated patients with severe CRSwNP and may serve as a pragmatic threshold for interpreting olfactory outcomes.
- 21 June 2026
- Published by Taylor & Francis in Acta Oto-Laryngologica
- Vol. 146 (10) , 1-9
Open AccessThe minimal clinically important difference for the Sniffin’ Sticks Identification Test-16 in patients with chronic rhinosinusitis with nasal polyps treated with biologics
The Minimal Clinically Important Difference (MCID) reflects the smallest change in a test score perceived as relevant by the patient. MCIDs vary according to disease and clinical context. The Sniffin' Sticks Identification Test 16 (SSIT-16) is a commonly used smell assessment tool, but its MCID in severe chronic rhinosinusitis with nasal polyps (CRSwNP) is unknown. To determine the MCID of SSIT-16 in severe CRSwNP treated with biologics. We analysed change scores from baseline to week 24 in 313 patients. The MCID was estimated using anchor-based and distribution-based methods. Anchors included a visual analogue scale (VAS) for smell, the rhinologic domain of SNOT-22, and the smell/taste item of SNOT-22. Distribution-based analyses included half a standard deviation of baseline SSIT-16 scores, the standard error of measurement (SEM), and the individual-level smallest detectable change. The smell VAS performed best and was therefore chosen as the primary anchor. The optimal ΔSSIT-16 cut-off, balancing sensitivity (78%) and specificity (84%), was 3.5 points. This estimate was supported by distribution-based, sensitivity, and subgroup analyses. An improvement of approximately 3.5 SSIT-16 points appears to reflect clinically meaningful change in biologically treated patients with severe CRSwNP and may serve as a pragmatic threshold for interpreting olfactory outcomes.
- Open Access
- 13 April 2026
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (8) , 914-916
Functional Endoscopic Sinus Surgery in Adults With CRSwNP Treated With Mepolizumab: Airway Physiology Outcomes From a Randomised Controlled Trial
Summary: Airway hyperresponsiveness improved after mepolizumab, particularly for indirect bronchial challenge. Analyses were exploratory and not pre‐specified in the randomised trial protocol.
- 13 April 2026
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (8) , 914-916
Open AccessFunctional Endoscopic Sinus Surgery in Adults With CRSwNP Treated With Mepolizumab: Airway Physiology Outcomes From a Randomised Controlled Trial
Summary: Airway hyperresponsiveness improved after mepolizumab, particularly for indirect bronchial challenge. Analyses were exploratory and not pre‐specified in the randomised trial protocol.
- RetractionOpen Access
- 21 February 2026
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 26 (1) , 14
Retraction Note: Restoring the Sense of Smell: A Systematic Review and Meta-Analysis of Biologic Therapies for Chronic Rhinosinusitis with Nasal Polyps
- 21 February 2026
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 26 (1) , 14
RetractionOpen AccessRetraction Note: Restoring the Sense of Smell: A Systematic Review and Meta-Analysis of Biologic Therapies for Chronic Rhinosinusitis with Nasal Polyps
- RetractedOpen Access
- 20 November 2025
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 25 (1) , 54
RETRACTED ARTICLE: Restoring the Sense of Smell: A Systematic Review and Meta-Analysis of Biologic Therapies for Chronic Rhinosinusitis with Nasal Polyps
Purpose of Review Smell loss is among the most debilitating symptoms of chronic rhinosinusitis with nasal polyps (CRSwNP). We aimed to synthesize current evidence on the smell-restoring efficacy of biologics, focusing on outcomes measured by psychophysical tests. Recent Findings Biologics mark a paradigm shift in the management of refractory CRSwNP, offering targeted, effective and safe treatment options. However, their relative impact on psychophysical smell outcomes remains uncertain. With several biologics now approved and real-world evidence emerging, a comprehensive evaluation is needed. Summary This is a systematic review and meta-analysis of 8 RCTs (n = 2,024) and an additional review of 20 cohorts (n = 1,685). Among RCTs, biologic treatment produced a moderate to large pooled improvement in psychophysical smell scores (standardized mean difference, [SMD] = 0.72 (95% CI 0.32–1.13), p = 0.0004). The effect differed between drugs (χ² = 23.95, p < 0.0002). Dupilumab showed the largest improvements across four RCTs (SMD = 1.16, 95% CI = 0.35–1.97). In single RCTs, benralizumab showed large effect (1.03, 0.55–1.51), tezepelumab (0.56, 0.46–0.67), telikibart (0.35, 0.11–0.59), and omalizumab (0.27, 0.15–0.40) yielded modest but significant improvements. Mepolizumab showed no effect (0.1330 (95% CI −0.2490–0.5150). Blood-eosinophil level correlated with treatment response (p < 0.001). The cohort studies supported the findings (SMD = 1.20, 95% CI = 0.99–1.42), though most data were derived from studies of dupilumab. Overall, biologics substantially improve psychophysically measured olfactory function in CRSwNP. Future head-to-head trials are warranted to delineate comparative efficacy of smell recovery.
- 20 November 2025
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 25 (1) , 54
RetractedOpen AccessRETRACTED ARTICLE: Restoring the Sense of Smell: A Systematic Review and Meta-Analysis of Biologic Therapies for Chronic Rhinosinusitis with Nasal Polyps
Purpose of Review Smell loss is among the most debilitating symptoms of chronic rhinosinusitis with nasal polyps (CRSwNP). We aimed to synthesize current evidence on the smell-restoring efficacy of biologics, focusing on outcomes measured by psychophysical tests. Recent Findings Biologics mark a paradigm shift in the management of refractory CRSwNP, offering targeted, effective and safe treatment options. However, their relative impact on psychophysical smell outcomes remains uncertain. With several biologics now approved and real-world evidence emerging, a comprehensive evaluation is needed. Summary This is a systematic review and meta-analysis of 8 RCTs (n = 2,024) and an additional review of 20 cohorts (n = 1,685). Among RCTs, biologic treatment produced a moderate to large pooled improvement in psychophysical smell scores (standardized mean difference, [SMD] = 0.72 (95% CI 0.32–1.13), p = 0.0004). The effect differed between drugs (χ² = 23.95, p < 0.0002). Dupilumab showed the largest improvements across four RCTs (SMD = 1.16, 95% CI = 0.35–1.97). In single RCTs, benralizumab showed large effect (1.03, 0.55–1.51), tezepelumab (0.56, 0.46–0.67), telikibart (0.35, 0.11–0.59), and omalizumab (0.27, 0.15–0.40) yielded modest but significant improvements. Mepolizumab showed no effect (0.1330 (95% CI −0.2490–0.5150). Blood-eosinophil level correlated with treatment response (p < 0.001). The cohort studies supported the findings (SMD = 1.20, 95% CI = 0.99–1.42), though most data were derived from studies of dupilumab. Overall, biologics substantially improve psychophysically measured olfactory function in CRSwNP. Future head-to-head trials are warranted to delineate comparative efficacy of smell recovery.
- Open Access
- 6 June 2023
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 25, e45210
Using Virtual Reality Head-Mounted Displays to Assess Skills in Emergency Medicine: Validity Study
Background: Many junior doctors must prepare to manage acutely ill patients in the emergency department. The setting is often stressful, and urgent treatment decisions are needed. Overlooking symptoms and making wrong choices may lead to substantial patient morbidity or death, and it is essential to ensure that junior doctors are competent. Virtual reality (VR) software can provide standardized and unbiased assessment, but solid validity evidence is necessary before implementation. Objective: This study aimed to gather validity evidence for using 360-degree VR videos with integrated multiple-choice questions (MCQs) to assess emergency medicine skills. Methods: Five full-scale emergency medicine scenarios were recorded with a 360-degree video camera, and MCQs were integrated into the scenarios to be played in a head-mounted display. We invited 3 groups of medical students with different experience levels to participate: first- to third-year medical students (novice group), last-year medical students without emergency medicine training (intermediate group), and last-year medical students with completed emergency medicine training (experienced group). Each participant’s total test score was calculated based on the number of correct MCQ answers (maximum score of 28), and the groups’ mean scores were compared. The participants rated their experienced presence in emergency scenarios using the Igroup Presence Questionnaire (IPQ) and their cognitive workload with the National Aeronautics and Space Administration Task Load Index (NASA-TLX). Results: We included 61 medical students from December 2020 to December 2021. The experienced group had significantly higher mean scores than the intermediate group (23 vs 20; P=.04), and the intermediate group had significantly higher scores than the novice group (20 vs 14; P<.001). The contrasting groups’ standard-setting method established a pass-or-fail score of 19 points (68% of the maximum possible score of 28). Interscenario reliability was high, with a Cronbach α of 0.82. The participants experienced the VR scenarios with a high degree of presence with an IPQ score of 5.83 (on a scale from 1-7), and the task was shown to be mentally demanding with a NASA-TLX score of 13.30 (on a scale from 1-21). Conclusions: This study provides validity evidence to support using 360-degree VR scenarios to assess emergency medicine skills. The students evaluated the VR experience as mentally demanding with a high degree of presence, suggesting that VR is a promising new technology for emergency medicine skills assessment.
- 6 June 2023
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 25, e45210
Open AccessUsing Virtual Reality Head-Mounted Displays to Assess Skills in Emergency Medicine: Validity Study
Background: Many junior doctors must prepare to manage acutely ill patients in the emergency department. The setting is often stressful, and urgent treatment decisions are needed. Overlooking symptoms and making wrong choices may lead to substantial patient morbidity or death, and it is essential to ensure that junior doctors are competent. Virtual reality (VR) software can provide standardized and unbiased assessment, but solid validity evidence is necessary before implementation. Objective: This study aimed to gather validity evidence for using 360-degree VR videos with integrated multiple-choice questions (MCQs) to assess emergency medicine skills. Methods: Five full-scale emergency medicine scenarios were recorded with a 360-degree video camera, and MCQs were integrated into the scenarios to be played in a head-mounted display. We invited 3 groups of medical students with different experience levels to participate: first- to third-year medical students (novice group), last-year medical students without emergency medicine training (intermediate group), and last-year medical students with completed emergency medicine training (experienced group). Each participant’s total test score was calculated based on the number of correct MCQ answers (maximum score of 28), and the groups’ mean scores were compared. The participants rated their experienced presence in emergency scenarios using the Igroup Presence Questionnaire (IPQ) and their cognitive workload with the National Aeronautics and Space Administration Task Load Index (NASA-TLX). Results: We included 61 medical students from December 2020 to December 2021. The experienced group had significantly higher mean scores than the intermediate group (23 vs 20; P=.04), and the intermediate group had significantly higher scores than the novice group (20 vs 14; P<.001). The contrasting groups’ standard-setting method established a pass-or-fail score of 19 points (68% of the maximum possible score of 28). Interscenario reliability was high, with a Cronbach α of 0.82. The participants experienced the VR scenarios with a high degree of presence with an IPQ score of 5.83 (on a scale from 1-7), and the task was shown to be mentally demanding with a NASA-TLX score of 13.30 (on a scale from 1-21). Conclusions: This study provides validity evidence to support using 360-degree VR scenarios to assess emergency medicine skills. The students evaluated the VR experience as mentally demanding with a high degree of presence, suggesting that VR is a promising new technology for emergency medicine skills assessment.
- Open Access
- 21 December 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Using Virtual Reality Head-Mounted Displays to Assess Skills in Emergency Medicine: Validity Study (Preprint)
BACKGROUND Many junior doctors must prepare to manage acutely ill patients in the emergency department. The setting is often stressful, and urgent treatment decisions are needed. Overlooking symptoms and making wrong choices may lead to substantial patient morbidity or death, and it is essential to ensure that junior doctors are competent. Virtual reality (VR) software can provide standardized and unbiased assessment, but solid validity evidence is necessary before implementation. OBJECTIVE This study aimed to gather validity evidence for using 360-degree VR videos with integrated multiple-choice questions (MCQs) to assess emergency medicine skills. METHODS Five full-scale emergency medicine scenarios were recorded with a 360-degree video camera, and MCQs were integrated into the scenarios to be played in a head-mounted display. We invited 3 groups of medical students with different experience levels to participate: first- to third-year medical students (novice group), last-year medical students without emergency medicine training (intermediate group), and last-year medical students with completed emergency medicine training (experienced group). Each participant’s total test score was calculated based on the number of correct MCQ answers (maximum score of 28), and the groups’ mean scores were compared. The participants rated their experienced presence in emergency scenarios using the Igroup Presence Questionnaire (IPQ) and their cognitive workload with the National Aeronautics and Space Administration Task Load Index (NASA-TLX). RESULTS We included 61 medical students from December 2020 to December 2021. The experienced group had significantly higher mean scores than the intermediate group (23 vs 20; P=.04), and the intermediate group had significantly higher scores than the novice group (20 vs 14; P<.001). The contrasting groups’ standard-setting method established a pass-or-fail score of 19 points (68% of the maximum possible score of 28). Interscenario reliability was high, with a Cronbach α of 0.82. The participants experienced the VR scenarios with a high degree of presence with an IPQ score of 5.83 (on a scale from 1-7), and the task was shown to be mentally demanding with a NASA-TLX score of 13.30 (on a scale from 1-21). CONCLUSIONS This study provides validity evidence to support using 360-degree VR scenarios to assess emergency medicine skills. The students evaluated the VR experience as mentally demanding with a high degree of presence, suggesting that VR is a promising new technology for emergency medicine skills assessment.
- 21 December 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessUsing Virtual Reality Head-Mounted Displays to Assess Skills in Emergency Medicine: Validity Study (Preprint)
BACKGROUND Many junior doctors must prepare to manage acutely ill patients in the emergency department. The setting is often stressful, and urgent treatment decisions are needed. Overlooking symptoms and making wrong choices may lead to substantial patient morbidity or death, and it is essential to ensure that junior doctors are competent. Virtual reality (VR) software can provide standardized and unbiased assessment, but solid validity evidence is necessary before implementation. OBJECTIVE This study aimed to gather validity evidence for using 360-degree VR videos with integrated multiple-choice questions (MCQs) to assess emergency medicine skills. METHODS Five full-scale emergency medicine scenarios were recorded with a 360-degree video camera, and MCQs were integrated into the scenarios to be played in a head-mounted display. We invited 3 groups of medical students with different experience levels to participate: first- to third-year medical students (novice group), last-year medical students without emergency medicine training (intermediate group), and last-year medical students with completed emergency medicine training (experienced group). Each participant’s total test score was calculated based on the number of correct MCQ answers (maximum score of 28), and the groups’ mean scores were compared. The participants rated their experienced presence in emergency scenarios using the Igroup Presence Questionnaire (IPQ) and their cognitive workload with the National Aeronautics and Space Administration Task Load Index (NASA-TLX). RESULTS We included 61 medical students from December 2020 to December 2021. The experienced group had significantly higher mean scores than the intermediate group (23 vs 20; P=.04), and the intermediate group had significantly higher scores than the novice group (20 vs 14; P<.001). The contrasting groups’ standard-setting method established a pass-or-fail score of 19 points (68% of the maximum possible score of 28). Interscenario reliability was high, with a Cronbach α of 0.82. The participants experienced the VR scenarios with a high degree of presence with an IPQ score of 5.83 (on a scale from 1-7), and the task was shown to be mentally demanding with a NASA-TLX score of 13.30 (on a scale from 1-21). CONCLUSIONS This study provides validity evidence to support using 360-degree VR scenarios to assess emergency medicine skills. The students evaluated the VR experience as mentally demanding with a high degree of presence, suggesting that VR is a promising new technology for emergency medicine skills assessment.
- 16 May 2016
- Vol. 178 (20)
[Blaschko lines in the emergency room].